ZL0420

Cell experiment:

hSAECs are first pretreated with a series final concentrations of BRD4 inhibitors from 0.01 nM to 100 µM for 24 hours and are then added poly(I:C) at 10 µg/mL for another 4 hours prior to harvesting the cells. The harvested cells are first ished with PBS twice and then the total RNA is extracted using acid guanidinium phenol extraction. The total RNA is further reverse-transcribed for gene expression analysis by Q-RT-PCR[1].

Animal experiment:

Mice[1]C57BL/6 mice are pre-treated in the absence or presence of the ZL0420 [10 mg/kg body weight, via the intraperitoneal route] one day prior to poly(I:C) stimulation. The next day, animals are given another dose of ZL0420 immediately followed by intranasal (i.n.) administration of phosphate-buffered saline (PBS, 50 µL) or poly(I:C) (300 µg dissolved in 50 µL PBS). One day later, the mice are euthanized. The bronchoalveolar lavage fluid (BALF) and lung tissues of treated mice are collected for further analysis[1].

References:

[1]. Liu Z, et al. Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation. Eur J Med Chem. 2018 May 10;151:450-461.